FDA Approvals, News & UpdatesLung Cancer

Retevmo First Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions

In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy.
November 2020 – Lung Cancer

On May 8, 2020, the FDA accelerated the approval of Retevmo (selpercatinib; from Lilly Oncology), an oral kinase inhibitor, for the treatment of metastatic non–small-cell lung cancer (NSCLC), as well as for patients with several types of metastatic thyroid cancer that are associated with RET fusions or mutations, as determined by an FDA-approved test. Retevmo is the first drug to be approved specifically for patients with cancer that is linked to RET mutations or fusions.

“The FDA is committed to reviewing treatments like Retevmo that are targeted to specific subsets of patients with cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Retevmo was based on the results of a clinical trial of patients who had 1 of 3 types of tumors associated with RET fusions or mutations, including patients with metastatic NSCLC and RET fusions or mutations and patients with 2 different types of metastatic thyroid cancer.

The study included 105 adults with NSCLC and RET fusion who had previously received chemotherapy. Overall, 64% of the patients responded to treatment with Retevmo, and the responses lasted 6 or more months in the majority (81%) of the patients. Similar results were seen in the 39 patients with NSCLC and RET fusion who had not received any previous therapy for lung cancer. The study also included patients with metastatic thyroid cancer, who showed similar positive responses to Retevmo.

The most common side effects with Retevmo were increased laboratory test results, including AST, ALT, and blood glucose levels; decreased white blood cell count, albumin, and calcium levels; dry mouth; diarrhea; increased creatinine, alkaline phosphatase, and hypertension; fatigue; swelling in the body or limbs; low platelet count; increased cholesterol; rash; constipation; and decreased sodium levels.

The serious side effects with Retevmo include liver side effects, elevated blood pressure, abnormal heartbeat, bleeding, and allergic reactions. Retevmo should be stopped temporarily or permanently in patients with liver side effects.

Share this:

Recommended For You
Lung CancerIssue Introductions
Looking at Lung Cancer without Stigma
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
In her introduction to this special issue on Lung Cancer, Lillie Shockney, RN, BS, MAS, emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease.
Patient StoriesLung CancerPatient Advocacy
Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
By Montessa Lee
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action.
Lung CancerImmunotherapyBiomarkers
Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC.
Last modified: January 7, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest